For an adult with chronic heart failure and iron deficiency (ferritin <100 µg/L or 100‑300 µg/L with transferrin saturation <20 %), is intravenous iron infusion preferred over oral iron supplementation?

Intravenous Iron Infusion is Strongly Preferred Over Oral Iron in Heart Failure with Iron Deficiency

For adults with chronic heart failure and iron deficiency (ferritin <100 µg/L or 100–300 µg/L with TSAT <20%), intravenous iron infusion—specifically ferric carboxymaltose—is the recommended treatment; oral iron supplementation is ineffective and should not be used. 1, 2

Why Intravenous Iron is Superior

Oral Iron is Ineffective in Heart Failure

• The IRONOUT-HF trial definitively demonstrated that oral iron provides no functional or symptomatic benefit in heart failure patients. 2
• Hepcidin—an inflammatory peptide elevated in heart failure—blocks intestinal iron absorption, rendering oral supplementation futile regardless of dose. 2
• Oral iron absorption is further impaired by decreased gastrointestinal perfusion in heart failure, and up to 60% of patients experience gastrointestinal side effects that worsen compliance. 3
• Current European Society of Cardiology and American College of Cardiology guidelines explicitly state that oral iron has not been shown to be effective in chronic heart failure. 1, 2

Intravenous Iron Delivers Proven Clinical Benefits

• Intravenous ferric carboxymaltose is the only effective route for iron repletion in heart failure. 2
• The FAIR-HF trial (randomized, double-blind) showed that weekly IV ferric carboxymaltose significantly improved NYHA functional class, 6-minute walk distance, and quality-of-life scores—independent of whether patients were anemic or not. 2
• The CONFIRM-HF trial demonstrated sustained improvements in exercise capacity over 52 weeks and a reduction in heart failure hospitalizations. 2
• The AFFIRM-AHF trial (hospitalized HF patients with EF <50%) reported a 26% relative reduction in heart failure rehospitalizations (RR 0.74; 95% CI 0.58–0.94). 2
• Meta-analyses suggest beneficial effects on cardiovascular mortality rates. 4

Diagnostic Criteria: Use Both Ferritin AND Transferrin Saturation

Standard Guideline Definition

• Iron deficiency is defined as ferritin <100 ng/mL (any TSAT) OR ferritin 100–300 ng/mL with TSAT <20%. 1, 2, 5
• All symptomatic heart failure patients should undergo simultaneous measurement of serum ferritin and TSAT at baseline. 2

Critical Nuance: TSAT <20% is the Most Reliable Marker

• Recent high-quality evidence challenges reliance on ferritin alone. Patients with TSAT <20%—but not those with ferritin <100 ng/mL alone—show consistent benefit from IV iron. 6, 7, 8, 9, 10
• In randomized trials, IV iron decreased the risk of cardiovascular death or total heart failure hospitalization in patients with TSAT <20% (risk ratio 0.67 [0.49–0.92]) but not in patients with TSAT ≥20% (risk ratio 0.99 [0.74–1.30]). 7
• TSAT <20% directly reflects hypoferremia and iron-deficient erythropoiesis, making it the most reliable functional marker. 2, 8, 10
• Lower TSAT and serum iron—but not ferritin—are associated with more signs of congestion by ultrasound, worse exercise capacity, and poorer prognosis. 8, 10

Common Pitfall to Avoid

• Never rely on ferritin alone; always interpret together with TSAT. 2
• Ferritin is an acute-phase reactant and can be falsely elevated by inflammation, infection, or liver disease. 2
• Patients with ferritin 100–300 ng/mL and TSAT <20% have functional iron deficiency despite "normal" ferritin and benefit from IV iron because it bypasses hepcidin-mediated sequestration. 2

Indications for Intravenous Iron Therapy

• IV ferric carboxymaltose should be considered in symptomatic patients with chronic systolic heart failure (LVEF <40%) and iron deficiency (Class IIa, Level A recommendation). 1
• The 2016 European Society of Cardiology heart failure guidelines recommend IV iron therapy with ferric carboxymaltose (Class IIa, Level A). 1
• American College of Cardiology guidelines recommend IV iron for patients with NYHA class II–III heart failure and iron deficiency. 5
• Benefits occur independent of anemia status—do not withhold IV iron from non-anemic patients with iron deficiency. 2

Dosing Protocol for Ferric Carboxymaltose

Calculation and Administration

• Total iron requirement is calculated based on body weight and hemoglobin level, not ferritin or TSAT. 1, 2
• Ferric carboxymaltose contains 50 mg iron/mL; single IV doses of 500–1000 mg are administered. 1, 2
• The maximum recommended cumulative dose is 1000 mg iron (20 mL) per week. 1
• It can be given as an undiluted slow bolus injection (100 mg/min, or 15 minutes for a 1000 mg dose) or as an infusion. 1, 2

Dose by Hemoglobin and Weight

Hemoglobin (g/dL)	<35 kg	35–70 kg	≥70 kg
<10	500 mg	1500 mg	2000 mg
10–14	500 mg	1000 mg	1500 mg
14–15	500 mg (any weight)	—	—

2

Important Restrictions

• Do not administer IV iron when hemoglobin exceeds 15 g/dL. 2
• Patients should be observed for adverse effects for at least 30 minutes following each IV injection. 1, 2

Monitoring After Intravenous Iron

Timing of Reassessment

• Do not obtain iron studies within 4 weeks of an IV iron dose, as circulating iron interferes with assay accuracy. 2, 11
• The optimal reassessment window is 4–8 weeks post-infusion. 2
• Re-measure ferritin and TSAT at the next scheduled visit, preferably ≥3 months after the last infusion. 1, 2
• Ongoing surveillance of ferritin and TSAT should occur 1–2 times per year or sooner if clinical status changes or hemoglobin falls. 2

Treatment Targets

• Aim for a post-treatment TSAT ≥20% to ensure sufficient iron availability for erythropoiesis. 2
• Initiate re-treatment when ferritin drops below 100 ng/mL or hemoglobin falls below normal range (12 g/dL for women, 13 g/dL for men). 11

Monitoring for Adverse Effects

• Monitor for hypophosphatemia, particularly with repeated dosing of ferric carboxymaltose. 2, 11
• Follow up hemoglobin every 4 weeks until normalized, then every 3 months for the first year. 11

Contraindications and Cautions

Absolute Contraindications

• Hypersensitivity to ferric carboxymaltose or any of its excipients. 1, 5
• Known serious hypersensitivity to other parenteral iron products. 1, 5
• Anemia not attributed to iron deficiency (e.g., other microcytic anemias). 1
• Evidence of iron overload or disturbances in iron utilization. 1, 5

Use with Caution

• Acute or chronic infection—treatment should be stopped in patients with ongoing bacteremia. 1, 5
• Known drug allergies, including history of severe asthma, eczema, or other atopic allergies (increased risk of hypersensitivity). 1, 5
• Immune or inflammatory conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis). 1, 5

Evidence Gaps

• No clinical evidence for IV ferric carboxymaltose in patients with HFpEF (LVEF ≥50%) and limited evidence in HFmrEF (LVEF 40–49%). 1
• The efficacy and safety have not been evaluated in patients with hemoglobin >15 g/dL. 1

Management of Elevated Ferritin

• Ferritin >300 ng/mL with TSAT >50% indicates true iron overload—evaluate for hereditary hemochromatosis or other iron-loading disorders and avoid further iron administration. 2
• Patients with ferritin 100–300 ng/mL and TSAT <20% have functional iron deficiency despite "normal" ferritin and should receive IV iron. 2

Where and Who Should Administer

• IV ferric carboxymaltose can be administered in the hospital or community setting. 1
• General cardiologists can safely administer IV iron after appropriate training in recognition and management of hypersensitivity reactions. 6